


### Amendments to the Claims

1. (Currently amended) A compound of formula (I):



or pharmaceutically acceptable salts, or solvates, or N<sub>10</sub>-C<sub>44</sub> imine bond prodrugs thereof,  
 wherein:

R<sup>6</sup>, R<sup>7</sup> and R<sup>9</sup> are independently selected from H, R, OH, OR, SH, SR, NH<sub>2</sub>, NHR, N[[H]]RR',  
 nitro, Me<sub>3</sub>Sn and halo;


where R and R' are independently selected from C<sub>1-7</sub> alkyl, heterocyclyl having 3 to 20 ring  
 atoms of which 1 to 10 are ring heteroatoms independently selected from the group consisting  
 N, O and S and aryl or heteroaryl having 5 to 20 ring atoms, the heteroaryl groups having one or  
 more heteratoms independently selected from the group consisting of N, O and S;

R<sup>8</sup> is selected from H, R, OH, OR, SH, SR, NH<sub>2</sub>, NHR, N[[H]]RR', nitro, Me<sub>3</sub>Sn and halo, or the  
 compound is a dimer with each monomer being of formula (I), where the R<sup>8</sup> groups of each  
 monomers form together a dimer bridge having the formula -X-R"-X- linking the monomers,  
 where R" is a C<sub>3-12</sub> alkylene group, which chain may be interrupted by one or more heteroatoms  
 selected from the group consisting of O, S, and NH, and/or aromatic rings selected from the  
 group consisting of benzene and pyridine, and each X is independently selected from O, S, or  
 NH;

or any pair of adjacent groups from R<sup>6</sup> to R<sup>9</sup> together form a group -O-(CH<sub>2</sub>)<sub>p</sub>-O-, where p is 1 or  
 2; and

R<sup>2</sup> is a naphthyl group, optionally substituted by one or more substituents selected from the group  
 consisting of halo, C<sub>1-7</sub> alkyl, C<sub>1-7</sub> alkoxy, C<sub>3-20</sub> heterocyclyl, C<sub>5-20</sub> heterocyclyl, , and aryl or  
 heteroaryl having 5 to 20 ring atoms, the heteroaryl groups having one or more heteratoms  
 independently selected from the group consisting of N, O and S;

2. Cancelled.
3. Cancelled.
4. (Previously presented) A compound according to claim 1, wherein  $R^9$  is H.
5. (Previously presented) A compound according to claim 1, wherein  $R^6$  is H.
6. (Previously presented) A compound according to claim 1, wherein  $R^7$  and  $R^8$  (when the compound is not a dimer) are selected from OMe and  $OCH_2Ph$ .
7. Cancelled.
8. (Previously presented) A pharmaceutical composition containing a compound of claim 1, and a pharmaceutically acceptable carrier or diluent.
9. Cancelled.
10. (Previously presented) A method of treatment of melanomas, or breast, renal, or lung cancer, comprising administering to a subject in need of treatment a therapeutically-effective amount of a compound of claim 1.
11. (Currently amended) A compound of formula (II)



wherein

$R^2$  is a naphthyl group, optionally substituted by one or more substituents selected from the group consisting of halo,  $C_{1-7}$  alkyl,  $C_{1-7}$  alkoxy,  $C_{3-20}$  heterocyclyl,  $C_{5-20}$  heterocyclyl, , and aryl or heteroaryl having 5 to 20 ring atoms, the heteroaryl groups having one or more heteratoms independently selected from the group consisting of N, O and S;

$R^6$ ,  $R^7$  and  $R^9$  are independently selected from H, R, OH, OR, SH, SR,  $NH_2$ , NHR,  $NRR'$ , nitro,  $Me_3Sn$  and halo;

$R^8$  is selected from H, R, OH, OR, SH, SR,  $NH_2$ , NHR,  $NRR'$ , nitro,  $Me_3Sn$  and halo, or the compound is a dimer with each monomer being of formula (II), where the  $R^8$  groups of each monomers form together a dimer bridge having the formula  $-X-R''-X-$  linking the monomers, where  $R''$  is a  $C_{3-12}$  alkylene group, which chain may be interrupted by one or more heteroatoms selected from the group consisting of O, S, and NH, and/or aromatic rings selected from the group consisting of benzene and pyridine, and each X is independently selected from O, S, or NH;

or any pair of adjacent groups from  $R^6$  to  $R^9$  together form a group  $-O-(CH_2)_p-O-$ , where p is 1 or 2;

$R_{10}$  is selected from:

- (a)  $4-NO_2-C_6H_4-CH_2-$ ;
- (b)  $2-NO_2-$ ,  $4,5-diMeO-C_6H_4-CH_2-$ ;
- (c)  $C_6H_5-CH_2-$ ; and
- (d)  $Me-SO_2-C_2H_4-$ ;

$R_{11}$  is selected from OH, OR or SR; and

R and  $R'$  are independently selected from  $C_{1-7}$  alkyl, heterocyclyl having 3 to 20 ring atoms of which 1 to 10 are ring heteroatoms independently selected from the group consisting N, O and S and aryl or heteroaryl having 5 to 20 ring atoms, the heteroaryl groups having one or more

~~heteratoms independently selected from the group consisting of N, O and S according to claim 1, wherein the N<sub>40</sub>-C<sub>41</sub> imine bond prodrug comprises a nitrogen protecting group on N<sub>40</sub> which can be removed *in vivo* and a hydroxyl, ester or thioester group on C<sub>41</sub>.~~

12. Cancelled.